Denosumab biosimilar - Jiangsu T-Mab Biopharma

Drug Profile

Denosumab biosimilar - Jiangsu T-Mab Biopharma

Alternative Names: TK-006

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jiangsu T-mab BioPharma
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Bone metastases

Most Recent Events

  • 10 Aug 2017 Jiangsu T-mab Biopharma plans a phase I trial for postmenopausal osteoporosis in China (NCT03242512)
  • 20 Jul 2017 Phase-I clinical trials in Bone metastases in China (SC) (NCT03239756)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top